Chengdu Olymvax Biopharmaceuticals Inc. (688319)
Market Closed
11 Aug, 06:57
SSE SSE Primary ¥
28. 66
+1.06
+3.8406%
¥
5.16B Market Cap
- P/E Ratio
0.15% Div Yield
9.7M Volume
- Eps
¥ 27.6
Previous Close Want to track 688319 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
688319 closed today higher at ¥28.66, an increase of 3.8406% from yesterday's close, completing a monthly decrease of -35.7255% or -¥15.93. Over the past 12 months, 688319 stock gained 13.505%.
688319 is not paying dividends to its shareholders.
The last earnings report, released on Apr 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
688319 Chart
People also search for
Chengdu Olymvax Biopharmaceuticals Inc. (688319) FAQ
What is the stock price today?
The current price is ¥28.66.
On which exchange is it traded?
Chengdu Olymvax Biopharmaceuticals Inc. is listed on SSE.
What is its stock symbol?
The ticker symbol is 688319.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.15%.
What is its market cap?
As of today, the market cap is 5.16B.
Has Chengdu Olymvax Biopharmaceuticals Inc. ever had a stock split?
No, there has never been a stock split.
Chengdu Olymvax Biopharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Shaowen Fan CEO | SSE Exchange | CNE1000051H8 ISIN |
| CN Country | 471 Employees | 25 Jun 2024 Last Dividend | - Last Split | - IPO Date |
Overview
Chengdu Olymvax Biopharmaceuticals Inc. is a biopharmaceutical entity that specializes in a wide array of activities concerning human vaccines. Established in 2009, this company is headquartered in Chengdu, China, and focuses primarily on the research and development, production, and distribution of vaccines. What distinguishes Chengdu Olymvax from its competitors is its commitment to innovation in vaccine technology, aiming to address a broad spectrum of infectious diseases. Moreover, the company also engages in promotion and application service business, thereby enhancing its footprint in the vaccine industry.
Products and Services
The product line of Chengdu Olymvax Biopharmaceuticals Inc. encompasses a range of vaccines aimed at combating various infectious diseases, as detailed below:
- Adsorbed Tetanus Vaccine: This vaccine is used to prevent tetanus, a serious infection caused by bacterial toxins affecting the nervous system.
- Hib Conjugate Vaccine: Aimed at preventing diseases caused by Haemophilus influenzae type b, such as meningitis and pneumonia, this vaccine is a critical component of pediatric immunization programs.
- Group A Streptococcus Vaccine: Specifically developed to provide immunity against infections caused by Group A Streptococcus bacteria, this vaccine targets conditions such as strep throat and skin infections.
- AC Conjugate Vaccine: This vaccine is designed to protect against meningococcal disease, which can lead to severe health problems like meningitis and sepsis, caused by groups A and C meningococcal bacteria.
- Vaccines for Haemophilus Influenzae Type b: Covering similar pathogens as the Hib conjugate vaccine, these vaccines are crucial in preventing a wide range of infections from H. influenzae.
- Group A and C Meningococcal Vaccine: Tailored to fend off diseases caused by groups A and C meningococcal bacteria, this vaccine plays a key role in preventing meningitis and bloodstream infections.
- Staphylococcus aureus Vaccine (Phase 3 Clinical Trial): Currently in Phase 3 clinical trials, this vaccine candidate is being developed to protect against infections caused by Staphylococcus aureus, a common cause of skin and wound infections, as well as more serious conditions like pneumonia and sepsis.
Contact Information
Address: No. 99 Tianxin Road, Chengdu, China, 611731
Phone: 86 28 6936 1111
Website: https://www.olymvax.com
